Phaseline

Targets › EBNA2

EBNA2: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2027.

Open in Phaseline: the race on EBNA2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Memorial Sloan Kettering Cancer CenterIn Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes
Allogeneic EBV-specific T cells genetically modified to express CAR targeting CD19
CD19, EBNA1, EBNA2, EBNA3Phase 1Acute Lymphocytic LeukemiaSep 2027

Conditions

Acute Lymphocytic Leukemia (1)

Modalities

other (1)

Companies

Memorial Sloan Kettering Cancer Center (1)

Related targets

CD19 (1) EBNA1 (1) EBNA3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.